SI-BONE announced preliminary Q4 2025 revenue of $56.2-$56.3 million (~15% growth) and full year 2025 revenue of $200.8-$200.9 million (~20% growth). The company reported ~1,640 active U.S. physicians (18% increase) and cash equivalents of ~$147.7 million with net cash generation of ~$2.0 million in Q4. Final audited results will be provided in late February 2026.

SI-Bone reported strong Q3 results with 21% revenue growth, narrowed net losses, and increased physician adoption, leading to a significant stock price surge.

SI-Bone reported a data breach on October 1, 2025, potentially exposing sensitive personal information including names, Social Security numbers, and medical details. A law firm is investigating potential legal action on behalf of affected customers.

Four under-the-radar companies - Porch Group, SunOpta, Tutor Perini, and Si-Bone - reported strong earnings in Q1 2025 and are seeing positive momentum in May.

Inogen is well-positioned for growth in the portable oxygen concentrator (POC) market, with a strong product portfolio and solid Q2 results. However, it faces stiff competition and forex volatility. The company's stock has outperformed the industry and the S&P 500 year-to-date.

QIAGEN announced the expansion of its strategic partnership with Bio-Manguinhos/Fiocruz, allowing the launch of an advanced PCR-based molecular screening platform to detect malaria and support epidemiological surveillance of Brazil's dengue epidemic. The collaboration is expected to have a positive impact on QIAGEN's market sentiment.

SI-BONE, Inc. (SIBN) announced that it will be participating in the upcoming Morgan Stanley Global Healthcare Conference, where management will host a fireside chat on September 4, 2024.

6 analysts have expressed a variety of opinions on SI-BONE (NASDAQ:SIBN) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 1 2 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $25.67, along with a high estimate of $27.00 and a low estimate of $24.00. Observing a 1.34% increase, the current average has risen from the previous average price target of $25.33. Decoding Analyst Ratings: A Detailed Look The analysis of recent analyst actions sheds light on the perception of SI-BONE by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Saxon Needham Maintains Buy $27.00 - David Saxon Needham Maintains Buy $27.00 - Matt O'Brien Piper Sandler Announces Overweight $25.00 - Drew Ranieri Morgan Stanley Raises Overweight $26.00 $25.00 Ross Osborn Cantor Fitzgerald Maintains Overweight $25.00 $25.00 Samuel Brodovsky Truist Securities Lowers Buy $24.00 $26.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related ...Full story available on Benzinga.com

Si-Bone (SIBN) delivered earnings and revenue surprises of 6.90% and 3.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Annual guidance increased to $164 million - $166 million, implying annual growth of ~18% - 20% Annual guidance increased to $164 million - $166 million, implying annual growth of ~18% - 20%

Organon's (OGN) first-quarter results are likely to reflect growth in its biosimilars and established brand franchises with lighter fertility product sales amid foreign exchange headwinds.

DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.